Harrow, Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $70.7 million (+10.9% year over year) and diluted EPS of -$0.46. It usually reports 33–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 9, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 10, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 33–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
71
+10.9%
|
-17
-445.7%
|
-0.46
-453.8%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
44
-7.6%
|
-28
-55.2%
|
-0.74
-48.0%
|
|
Feb 2, 2026
33 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
89
+33.3%
|
7
-2.2%
|
0.18
-6.1%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
72
+45.4%
|
1
+124.2%
|
0.03
+125.0%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
64
+30.2%
|
5
+177.2%
|
0.13
+172.2%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
48
+38.3%
|
-18
-31.1%
|
-0.50
-31.6%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
49
+43.8%
|
-4
+3.9%
|
-0.12
+7.7%
|
|
Aug 7, 2024
38 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HROW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Nashville, TN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1360214
- Former names
- HARROW HEALTH, INC. (until Sep 20, 2023); Imprimis Pharmaceuticals, Inc. (until Dec 17, 2018); TRANSDEL PHARMACEUTICALS INC (until Feb 27, 2012); Bywater Resources, Inc (until Sep 12, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.